Changchun Jinsai Pharmaceutical Co., Ltd. is a holding subsidiary of Changchun High-tech (stock code 000661). It was established in 1996. Its administrative headquarters and production headquarters are located in Changchun, and its marketing headquarters is located in Shanghai. The company integrates independent research and development, production, marketing and services. It is the largest genetic engineering pharmaceutical company in China and the largest recombinant human growth hormone manufacturer in Asia. It is the only genetic engineering company in the country that is a major project of new drug creation during the National “11th Five-Year Plan”. The new drug incubation base is also China’s first “Genetic Engineering Drug Quality Management Demonstration Center”. Its leading product, Jinlei®Saizen®, is the first brand of genetically recombinant human growth hormone in China. Data from the National Bureau of Statistics show that since 2005, the company's profit level has ranked first among all genetic engineering pharmaceutical companies in the country for six consecutive years.
In 1998, the company took the lead in launching China's first genetically recombinant human growth hormone powder; in 2005, it successfully launched Asia-Pacific's first genetically recombinant human growth hormone water injection; in 2008, the company successfully developed the world's first PEGylated long-acting growth hormone has obtained a national patent certificate. In 2008, the company launched a new drug with a national invention patent, the world's only rhGM-CSF gel. Because of its effective operations, Kinsey Pharmaceuticals has become the company with the most complete dosage forms and indications in the field of genetically recombinant human growth hormone, and aspires to be the leading position in China's genetically engineered pharmaceuticals.
With its dedicated and professional spirit of exploration and strong independent innovation capabilities, Kinsey Pharmaceuticals has become a leader in the field of children's growth and development treatment, with expertise in burns and scalds, assisted reproduction, anti-aging, tumors and other fields. It is also establishing a leading position with core competitive advantages.
Currently, Kinsey Pharmaceuticals has built an overall, series, and long-term product strategy in the field of children's growth and development to treat children with short stature, precocious puberty, gigantism, thyroid disease, insufficient sexual development, The successful development and transformation of a series of new products for children with mental developmental disorders have provided guarantee for the company's sustained, steady and rapid growth in performance. Looking forward to the future, the company will forge ahead, continue to innovate, and strive to establish Jinsey Pharmaceuticals, a century-old brand of "China's leading children's growth and development", and eventually become a world-class professional genetic medicine company.